Keywords: GlaxoSmithKline, Amplimmune, AMP-224, Cancer and other diseases

GlaxoSmithKline signs deal with Amplimmune worth more than $500 million for AMP-224 in cancer and other diseases

Article | 05 August 2010

Print This

US biotechnology firm Amplimmune, a four-year old spin-off from Johns Hopkins University, announced yesterday that it has entered into a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in